GLP-1 (1-37)

HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid

  • Description

  • Application Data

Description

GLP-1 (1-37) is a cleavage product of glucagon-like peptide (GLP) 1, lacking insulinotropic properties.

See full description

Application Data

Catalogue number crb1001037
Molecular Weight 4167
Sequence (one letter code)

HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid

Sequence (three letter code)

H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH

Purity >95%
cas 87805-34-3
Storage -20°C
References

Marx et al., (2010). Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell. Mol. Life Sci., 67: 3549. doi: 10.1007/s00018-010-0396-5.

Suzuki et al., (2003). Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci U S A., 100(9): 5034. PMID: 12702762.

Manufactured in: United Kingdom
Material Safety Data Sheet (MSDS)

Glucagon-like peptide (GLP) 1 is a post-translationally modified version of proglucagon. GLP-1 (1-37) is a naturally produced analog of GLP-1. Unlike truncated GLP-1, GLP-1 (1-37) does not alter food intake in rat models or pancreatic insulin secretion. GLP-1 (1-37) can induce insulin production in developing adult intestinal cells via upregulation of the ngn3 gene and its downstream targets. This can restore glucose homeostasis when implanted into diabetic mice. GLP-1 (1-37) may offer a  future treatment for diabetes mellitus. GLP-1 (1-37) can also inhibit chemokine-induced migration of human CD4-positive lymphocytes, an early step in atherogenesis. This raises the possibility that GLP-1 (1-37) is part of a novel mechanism to modulate vascular disease.

GLP-1 (1-37)

Cat No.Pack SizePriceQty.
0.5mg£130.00
1mg£260.00
Bulk Quote

Download Family PDF

You may also like…